NCT03973281

Brief Summary

This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device during delivery.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
420

participants targeted

Target at P75+ for not_applicable

Timeline
4mo left

Started Dec 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

22 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Dec 2019Aug 2026

First Submitted

Initial submission to the registry

May 31, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 4, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

December 11, 2019

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2026

Last Updated

September 17, 2025

Status Verified

September 1, 2025

Enrollment Period

6.6 years

First QC Date

May 31, 2019

Last Update Submit

September 16, 2025

Conditions

Keywords

Pelvic Floor Health, levator ani muscle injury, Pelvic Muscle Injury, Vaginal Delivery, Complications, Childbirth, prevention

Outcome Measures

Primary Outcomes (2)

  • The occurrence of pelvic muscle injury, defined as complete detachment of the levator ani muscle diagnosed via ultrasound imaging

    Use transperineal ultrasound to identify levator ani muscle detachment

    3-month Follow-up

  • The occurrence of pelvic muscle injury, defined as complete detachment of the levator ani muscle diagnosed via ultrasound imaging

    Use transperineal ultrasound to identify levator ani muscle detachment

    12-month Follow-up

Secondary Outcomes (17)

  • The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imaging

    3-Month Follow-up

  • The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imaging

    12-Month Follow-up

  • Length of 2nd Stage Labor

    Intra-Procedure

  • Levator Hiatal Area

    3-month and 12-month Follow-up

  • Perineal Lacerations

    Intra-Procedure

  • +12 more secondary outcomes

Study Arms (2)

Materna Prep Device

ACTIVE COMPARATOR

Materna Prep Device

Device: Materna Prep Device

Standard of Care (SOC)

OTHER

Standard of Care (SOC)

Other: Standard of Care (SOC)

Interventions

Materna Prep Device

Materna Prep Device

Standard of Care (SOC)

Standard of Care (SOC)

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is scheduled for vaginal birth.
  • Subject is gestating a single fetus.
  • Subject is nulliparous, or had a previous pregnancy terminated within 24 weeks gestation.
  • Subject is able and willing to comply with the protocol required follow-up visits.
  • Subject is able and willing to provide written informed consent prior to enrollment.
  • In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF), comply with the protocol requirements, and provide clinically relevant and reliable feedback regarding their experience with the device.
  • Subject receives epidural anesthesia during labor prior to enrollment.
  • Subject is 18 years of age or older at time of consent.

You may not qualify if:

  • Subject has high likelihood of less than 1 hour of potential device dilation time after she arrives at the hospital.
  • Subject is planning or requires a Caesarean-section prior to randomization.
  • Subject begins labor with less than 36 weeks gestation.
  • Subject has a neurological disorder that could cause pelvic floor dysfunction, such as multiple sclerosis or spinal cord injury.
  • Subject has a collagen-associated disorder that affects tissue elasticity, such as scleroderma or Ehlers-Danlos syndrome.
  • Subject has a localized (genital tract) or systemic infection.
  • Subject has a medical history which could lead to pelvic floor dysfunction, such as prior pelvic fractures, pelvic soft tissue injuries, or vaginal surgery.
  • Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.
  • Subject has placenta previa or vasa previa.
  • Subject has known significant chromosomal or structural fetal anomalies.
  • Subject has a category 2 and/or 3 fetal tracing that is unresolved.
  • Subject is observed to have friable, denuded, or markedly edematous vaginal tissue during the course of labor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (22)

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

Location

La Follette Ob/Gyn

Greenbrae, California, 94904, United States

Location

University of California Los Angeles

Los Angeles, California, 90095, United States

Location

El Camino Hospital

Mountain View, California, 94040, United States

Location

Christiana Care - Center for Women's & Children's Health

Newark, Delaware, 19718, United States

Location

MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

Location

USF Ob/Gyn

Tampa, Florida, 33606, United States

Location

The Healing Sanctuary

Idaho Falls, Idaho, 83404, United States

Location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

The Cooper Health System

Camden, New Jersey, 08103, United States

Location

Rutgers Robert Wood Johnson University Hospital

New Brunswick, New Jersey, 08901, United States

Location

Rutgers New Jersey Medical School

Newark, New Jersey, 07103, United States

Location

New York Presbyterian -Queens (NYPQ)

Flushing, New York, 11355, United States

Location

Columbia University Irving Medical Center

New York, New York, 10032, United States

Location

The Metro Health System

Cleveland, Ohio, 44109, United States

Location

The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States

Location

Oregon Health and Science University

Portland, Oregon, 97239, United States

Location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19140, United States

Location

Lewis Katz School of Medicine at Temple

Philadelphia, Pennsylvania, 19140, United States

Location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

Maximos Ob/Gyn

League City, Texas, 77573, United States

Location

Univ of Utah Ob/Gyn

Salt Lake City, Utah, 84108, United States

Location

MeSH Terms

Conditions

Pelvic Organ Prolapse

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The physician reading all ultrasound images will be blinded to randomization
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Randomized Control Study
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2019

First Posted

June 4, 2019

Study Start

December 11, 2019

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

August 30, 2026

Last Updated

September 17, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

General demographic data and outcome measures will be made available to other researchers

Locations